Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Tools & Technology » PCR » Immunexpress Nabs $599K BARDA Contract to Develop Sepsis Test for Coronavirus Patient Triage

Immunexpress Nabs $599K BARDA Contract to Develop Sepsis Test for Coronavirus Patient Triage

Jun 16, 2020
|
staff reporter

NEW YORK ─ Molecular diagnostics firm Immunexpress said Tuesday that it has been awarded a grant of up to $599,549 by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to develop its host response sepsis test, SeptiCyte Rapid, as a triage tool to help identify SARS-CoV-2 patients with an elevated risk for viral or secondary bacterial sepsis.

SeptiCyte Rapid is a gene expression assay that uses reverse-transcription PCR to quantify the relative expression levels of host response genes isolated from whole blood.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

COVAX's First Shipment

According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.

Support for Another

CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.

New Prototype Test

Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.

Cell Studies on SARS-CoV-2 Spike Variant, Host Transcriptomes, Glioma-Infiltrating T Cells

In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.

Feb
25
Featured Webinar

Virtual Molecular Tumor Board Series: Common Driver Mutations in ‘Off-Label’ Tumor Types

Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
18
Featured Webinar

Molecular Multi-Target Assay Design Coupled with Reflex Testing with SARS-CoV-2 Mutations in Mind

Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

What's Popular?

In Infectious Disease

  1. SARS-CoV-2 Test Pooling Studies Offer Insights for Implementing, Optimizing Approaches

  2. Adaptive Biotechnologies, LabCorp Expand Collaboration

  3. Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test

  4. Thermo Fisher Scientific Sued by New Jersey Lab Over COVID-19 Testing Problems

  5. BioMérieux Reports 21 Percent Revenue Growth in Q4

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.